SCHEMBL6359366

SCHEMBL6359366

NC(=O)S(=O)(=O)n1ccc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.54
HTT P42858 3/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
LMNA P02545 2/20 0.54
TSHR P16473 2/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.49
PKM P14618 1/20 0.49
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NOTUM Q6P988 1/20 0.44
RAB9A P51151 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636978 0.77 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL649929 0.77 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL8415487 0.77 HTR6 (0.66) HTR6HTTKMT2AMEN1LMNA
Benzene SCHEMBL29208974 0.76 HTR6 (0.65) HTR6HTTKMT2AMEN1LMNA
SCHEMBL6359369 0.74 HTR6 (0.58) HTR6HTTKMT2AMEN1LMNA
SCHEMBL24596834 0.73 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL29558089 0.73 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL4065276 0.73 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL10433225 0.70 HTR6 (0.58) HTR6HTTKMT2AMEN1LMNA
SCHEMBL29558135 0.70 HTR6 (1.00) HTR6HTTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085447-A1 Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors WARNER-LAMBERT COMPANY LLC 2005-04-21 US disclosed
WO-2005016926-A1 PYRIDO [3,4-D] PYRIMIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085447-A1 Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors MMP13, MMP9, MMP3 HTR6 2738/4885HTT 4555/4885KMT2A 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.